MoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics Target Price
Analysts' 12-month price predictions for MLTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$21.22
Average Target Price
$45.00
112.1% upside
112.1% upside1 analysts in the last 4 months
High: $45 | Low: $45
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-11 | H.C. Wainwright | $45 | 112.1% upside |  |
| 2026-02-24 | Oppenheimer | $35 | 64.9% upside | |
| 2026-01-14 | Goldman Sachs | $10 |  52.9% downside | |
| 2026-01-09 | H.C. Wainwright | $32 | 50.8% upside | |
| 2026-01-09 | UBS | $24 | 13.1% upside | |
| 2026-01-08 | UBS | $45 | 112.1% upside | |
| 2025-11-21 | H.C. Wainwright | $26 | 22.5% upside | |
| 2025-11-06 | Oppenheimer | $30 | 41.4% upside | |
| 2025-11-03 | H.C. WainwrightRaghuram Selvaraju | $30 | 41.4% upside | |
| 2025-10-07 | Oppenheimer | $25 | 17.8% upside | |
| 2025-09-30 | Goldman Sachs | $7 | 67% downside | |
| 2025-09-30 | NeedhamSerge Belanger | $20 | 5.7% downside | |
| 2025-09-30 | Guggenheim | $20 | 5.7% downside | |
| 2025-09-29 | Jefferies | $8 | 62.3% downside | |
| 2025-09-29 | RBC Capital | $10 | 52.9% downside | |
| 2025-03-18 | RBC Capital | $67 | 215.7% upside | |
| 2024-07-01 | H.C. WainwrightRaghuram Selvaraju | $100 | 371.3% upside | |
| 2024-04-02 | Goldman SachsRichard Law | $62 | 192.2% upside | |
| 2023-08-31 | NeedhamSerge Belanger | $76 | 258.2% upside | |